Cancer Research and Treatment

The Korean Cancer Association (대한암학회)
권호 표지
DOI QR코드

DOI QR Code

Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis

  • Lee, Han-Hong (Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Hur, Hoon (Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Kim, Soo-Hong (Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Park, Ae-Ryung (Department of Pharmacy, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Kim, Wook (Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Jeon, Hae-Myung (Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine)
  • Received : 2009.04.13
  • Accepted : 2009.09.08
  • Published : 2010.03.31
⟨ Previous Next ⟩

Abstract

Purpose: Treatment options for patients with advanced gastric cancer remain limited. Few studies have investigated the efficacy and tolerability of the combination regimen of oxaliplatin and 5-fluorouracil with leucovorin for patients with advanced gastric cancer. The goal of this study was to examine the efficacy and toxicity of a modified FOLFOX-6 (mFOLFOX-6) regimen as a first-line chemotherapy regimen for patients with advanced gastric cancer. Materials and Methods: From March, 2006, to December, 2007, 82 patients with advanced gastric cancer received 100 mg/$m^2$ oxaliplatin and 100 mg/$m^2$ leucovorin on the first day of treatment, followed by 2,400 mg/$m^2$ of 5-fluorouracil on the first and second days of treatment every 2 weeks as a first-line treatment. Results: The median age of the enrolled patients was 62 years (range; 30~75). Out of 82 patients, 34 cases (41.5%) were recurrent cases after curative resection, and the other 48 cases were unresectable or non-curative resectable cases. Their response was evaluated every 6 weeks. The overall response rate was 40.2%, with 2 (2.4%) complete response and 31 (37.8%) partial responses. The median time to progression (TTP) and overall survival (OS) time were 6.0 months (95% confidence interval [CI]: 4.69~7.31) and 13.0 months (7.99~18.0), respectively. The grade 3~4 hematologic toxicities observed included neutropenia (34.1%), thrombocytopenia (7.3%), and anemia (1.2%). The gastrointestinal toxicities observed included grade 3~4 nausea (9.8%) and vomiting (7.3%). Six patients (7.3%) experienced grade 3 neuropathy. No treatment-related deaths were recorded. Conclusion: The modified FOLFOX-6 regimen is effective and well tolerated as a first-line chemotherapy regimen for patients with advanced gastric cancer.

Keywords

References

  1. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163-8. https://doi.org/10.1023/A:1008243606668
  2. Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol. 2001;40:309-26. https://doi.org/10.1080/02841860121271
  3. Kohne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer in Europe. Oncology (Williston Park). 2000;14(12 Suppl 14):22-5.
  4. Wils J. Chemotherapy of metastatic gastric cancer. Gan To Kagaku Ryoho. 2000;27(Suppl 2):395-8.
  5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46. https://doi.org/10.1056/NEJMoa073149
  6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47.
  8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
  9. Becouarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: available data in noncolorectal gastrointestinal malignancies. Crit Rev Oncol Hematol. 2001;40:265-72. https://doi.org/10.1016/S1040-8428(01)00169-X
  10. Cavanna L, Artioli F, Codignola C, Lazzaro A, Rizzi A, Gamboni A, et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol. 2006;29:371-5. https://doi.org/10.1097/01.coc.0000221358.57089.f2
  11. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-8. https://doi.org/10.1200/JCO.2002.02.021
  12. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al. Phase I trial of 5- day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 1990;82:1046-50. https://doi.org/10.1093/jnci/82.12.1046
  13. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22:658-63. https://doi.org/10.1200/JCO.2004.07.042
  14. Ohtsu A. Chemotherapy for metastatic gastric cacner: past, present, and future. J Gastroenterol. 2008;43:256-64. https://doi.org/10.1007/s00535-008-2177-6
  15. Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, et al. Andormized phase 3 trials of irinotecan (CPT-11)+5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients. J Clin Oncol. 2005;23:16S(abstr 4003).
  16. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol. 2007; 25:18S(abstr LBA4513).
  17. Narahara H, Koizumi W, Hara T, Takagane T, Akiya M, Takagi K, et al. Randomized phase III study of S-1 alone versus S-1+cisplatin in the treatment for advanced gastric cancer (the SPIRITS trials) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. J Clin Oncol. 2007;25:18S(abstr 4514).
  18. Hebbar M, Tournigand C, Lledo G, Mabro M, Andre T, Louvet C, et al. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer invest. 2006;24:154-9. https://doi.org/10.1080/07357900500524397
  19. Kim JH, Oh DY, Kim YJ, Han SW, Choi IS, Kim DW, et al. Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal caner. J Korean Med Sci. 2005;20:806-10. https://doi.org/10.3346/jkms.2005.20.5.806
  20. Hwang WS, Chao TY, Lin SF, Chung CY, Chiu CF, Chang YF, et al. Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Anti-Cancer Drugs. 2008;19:283-8. https://doi.org/10.1097/CAD.0b013e3282f3fd17
  21. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92:1644-9. https://doi.org/10.1038/sj.bjc.6602573
  22. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-42. https://doi.org/10.1200/JCO.2007.13.9378
  23. Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5- fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol. 2000; 11:1477-83. https://doi.org/10.1023/A:1026520812351

Cited by

  1. Targeted Therapies for Gastric Cancer : Current Status vol.71, pp.11, 2010, https://doi.org/10.2165/11592530-000000000-00000
  2. Management of advanced gastric cancer vol.6, pp.2, 2010, https://doi.org/10.1586/egh.11.103
  3. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status vol.3, pp.2, 2010, https://doi.org/10.3892/ol.2011.496
  4. A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin vol.16, pp.3, 2010, https://doi.org/10.1007/s10157-012-0620-8
  5. Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies vol.44, pp.4, 2012, https://doi.org/10.4143/crt.2012.44.4.235
  6. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer vol.12, pp.None, 2010, https://doi.org/10.1186/1477-7819-12-115
  7. The clinical analysis of acute pancreatitis in colorectal cancer patients undergoing chemotherapy after operation vol.8, pp.None, 2010, https://doi.org/10.2147/ott.s88857
  8. Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status vol.16, pp.6, 2010, https://doi.org/10.7314/apjcp.2015.16.6.2355
  9. Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer vol.3, pp.5, 2010, https://doi.org/10.3892/mco.2015.592
  10. Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery vol.9, pp.None, 2010, https://doi.org/10.2147/ott.s99684
  11. Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX-4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer vol.17, pp.7, 2010, https://doi.org/10.14456/apjcp.2016.88/apjcp.2016.17.7.3277
  12. Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer vol.11, pp.None, 2010, https://doi.org/10.2147/ott.s149624
  13. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer vol.104, pp.1, 2010, https://doi.org/10.5301/tj.5000665
  14. Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer vol.81, pp.6, 2018, https://doi.org/10.1007/s00280-018-3576-x